CONCLUSIONS: Findings suggest no obvious significant adverse maternal or neonatal outcomes related to the use of buprenorphine + naloxone for the treatment of opioid dependence during pregnancy.
SCIENTIFIC SIGNIFICANCE: These initial findings underscore the need for future research to systematically examine the relative safety and effectiveness of buprenorphine + naloxone for mother, fetus, and child. (Am J Addict 2013; 22:252-254).
PMID: 23617867 [PubMed – in process] (Source: American Journal on Addictions)